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Introduction {#acn350909-sec-0005}
============

Allogeneic hematopoietic cell transplantation (allo‐HCT) is a compelling therapy with the potential of cure not only for numerous hematologic malignancies but also for a wide spectrum of disorders of the immune system.[1](#acn350909-bib-0001){ref-type="ref"} The theoretical basis of allo‐HCT is the intravenous infusion of progenitor cells capable to establish long‐term, stable myeloid, hematologic, and immunologic functions. The role of allo‐HCT has been established over the years. Therefore, its worldwide use is experiencing an upturn with alternative sources or donors and a significant improvement in supportive care. Despite advances in medical research and practice and use of less toxic agents allo‐HCT leads to complications with increased morbidity and mortality.[2](#acn350909-bib-0002){ref-type="ref"}

Among them, neurologic adverse events remain a largely understudied type of complication, despite their clinical impact and potential poor morbidity and mortality.[3](#acn350909-bib-0003){ref-type="ref"} A significant proportion of allo‐HCT complications concerns the nervous system both the central (CNS) or the peripheral (PNS).[4](#acn350909-bib-0004){ref-type="ref"} Drug toxicity, fungal infections, and immune‐mediated disorders prevail among other etiological factors.[5](#acn350909-bib-0005){ref-type="ref"} Furthermore, their severity varies from mild to fatal disorders.[4](#acn350909-bib-0004){ref-type="ref"}, [6](#acn350909-bib-0006){ref-type="ref"}

Those complications need to be recognized first by transplanters--hematologists. However, the problem lies in the vast number of various neurologic complications which either have been underestimated or not yet described systematically. The majority of existing studies focuses on a heterogeneous study population, for example, both adults and children, including allogeneic and autologous HCT.[7](#acn350909-bib-0007){ref-type="ref"}, [8](#acn350909-bib-0008){ref-type="ref"}, [9](#acn350909-bib-0009){ref-type="ref"} There is an unmet need to categorize these complications, describe their incidence and acknowledge their significant impact on survival.

The primary purpose of this systematic review and meta‐analysis is to provide a thorough summary of the incidence of the wide spectrum of neurologic complications after allo‐HCT for hematologic diseases in adults that have been scarcely described in literature. The secondary purpose is to assess the impact of those complications on overall survival.

Methods {#acn350909-sec-0006}
=======

This systematic review is reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta‐Analysis guidelines (Table [S1](#acn350909-sup-0001){ref-type="supplementary-material"}).[10](#acn350909-bib-0010){ref-type="ref"} A more thorough description of methods can be found in supplement part I (online only).

Search {#acn350909-sec-0007}
------

We conducted an extensive systematic literature search through 17 March, 2019 (Table [S2](#acn350909-sup-0001){ref-type="supplementary-material"}). Databases included PubMed, Embase, and Cochrane. The search was limited in studies published in English.

Eligibility criteria {#acn350909-sec-0008}
--------------------

The eligibility criteria were as follows: (a) adult population specified as patients 15 years old or older,[11](#acn350909-bib-0011){ref-type="ref"} (b) allo‐HCT for hematologic diseases, (c) neurologic disorders' diagnosis based on patient record. We deemed eligible all types of primary studies. We excluded only editorials and narrative reviews.

Data collection process and risk of bias {#acn350909-sec-0009}
----------------------------------------

All titles were downloaded into an Endnote library and then uploaded into Covidence. Duplicates were removed automatically. Two reviewers (MG, EG) working independently screened the titles and abstracts for eligibility. Then, full text was screened again in duplicate. A senior reviewer (MM) resolved any disagreement. For each article, at least one reviewer extracted the following: baseline characteristics of study and population, incidence and type of complication, time of the event after allo‐HCT, follow‐up, intervention, and outcome of neurologic event.

Two reviewers (MG, EG) independently assessed the quality of included studies. We divided studies according to their type: RCTs, cohort and case--control studies, case series, and case reports. We excluded case reports from further evaluation. We present them descriptively in the results and thoroughly in Table [S3](#acn350909-sup-0001){ref-type="supplementary-material"} (online only).

We assessed case series according to a tool proposed by Murad et al;[12](#acn350909-bib-0012){ref-type="ref"} case--control and cohort studies using the Newcastle--Ottawa scale (NOS);[13](#acn350909-bib-0013){ref-type="ref"} randomized trials using the Cochrane risk of bias assessment tool.[14](#acn350909-bib-0014){ref-type="ref"} The quality of evidence of the review was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool.[15](#acn350909-bib-0015){ref-type="ref"}

Summary measures and synthesis of results {#acn350909-sec-0010}
-----------------------------------------

The primary outcome was assessed in a form of a proportion of adult patients with the neurologic manifestation (n) from the total group of patients that received allo‐HCT for hematologic diseases (N). We performed meta‐analysis of proportions using the Freeman--Tukey double arcsine transformation,[16](#acn350909-bib-0016){ref-type="ref"} including only cohort studies. The number of available studies (≥5) and homogeneity of the included populations were the key parts for safe results.[17](#acn350909-bib-0017){ref-type="ref"} We chose random‐effects meta‐analysis. Heterogeneity was observed visually in the forest plot and quantified by the estimation of *I* ^2^ measure.[18](#acn350909-bib-0018){ref-type="ref"} Publication bias was assessed using Egger's test and visually inspecting produced funnel plot, although limitations of all methods in this occasion are considerable.[19](#acn350909-bib-0019){ref-type="ref"} Analyses were performed using OpenMeta\[Analyst\] or Stata®(version 11).[20](#acn350909-bib-0020){ref-type="ref"}, [21](#acn350909-bib-0021){ref-type="ref"}

For the secondary endpoint no synthesis of results was performed, since the data were expectedly diverse. Thus, we provide results from each study type separately, without excluding any type. The definition of case fatality rate was the proportion of patients who died because of neurologic complications from the patients that presented neurologic signs or symptoms after allo‐HCT.

Sensitivity and subgroup analyses {#acn350909-sec-0011}
---------------------------------

We have preplanned to perform a sensitivity analysis integrating the risk of bias assessment by excluding studies evaluated as high risk. We also have prespecified subgroup analyses according to the type of neurologic event.

Results {#acn350909-sec-0012}
=======

Study selection -- flow diagram {#acn350909-sec-0013}
-------------------------------

We retrieved a total of 33185 references which were imported for screening. The entire systematic literature review and selection of final records is illustrated by a PRISMA flow diagram in Figure [1](#acn350909-fig-0001){ref-type="fig"}.

![PRISMA Flow Diagram.](ACN3-6-2037-g001){#acn350909-fig-0001}

Taking into consideration the inclusion criteria mentioned above, our systematic review included one RCT, two case--control studies, 17 prospective cohort, 86 retrospective cohort studies, 21 case series, and 425 case reports. The total number of patients reported in these 552 references was 57.972. Of note, one cohort study by Colombo et al[22](#acn350909-bib-0022){ref-type="ref"} was retrospective from 1997 until 2007 and then prospective from 2008 to 2012 but the results of those time periods were presented together in the reports and could not provide separate data. Thus, we included it in retrospective cohorts.

Descriptive characteristics of each study category {#acn350909-sec-0014}
--------------------------------------------------

The included study categories were RCTs, case--control, case series, prospective and retrospective cohort studies as described before. Detailed characteristics of these 127 studies are presented in Tables [S4](#acn350909-sup-0001){ref-type="supplementary-material"}, [S5](#acn350909-sup-0001){ref-type="supplementary-material"} and [S6](#acn350909-sup-0001){ref-type="supplementary-material"} (online only). There was one RCT by Irle et al[23](#acn350909-bib-0023){ref-type="ref"} that reported drug‐related neurologic complications of methotrexate and cyclosporine as part of transplant‐related complications. Also, there were two case--control studies; one related to protozoan infectious CNS involvement[24](#acn350909-bib-0024){ref-type="ref"} and the other to TA‐TMA‐related neurologic events.[25](#acn350909-bib-0025){ref-type="ref"}

Among 17 prospective cohort studies identified, seven referred to drug‐related complications. Ishiyama et al[26](#acn350909-bib-0026){ref-type="ref"}, [27](#acn350909-bib-0027){ref-type="ref"} analyzed the safety of foscarnet sodium and the possibility of development of HHV‐6 encephalitis in two studies carried out in different periods. De Lima et al[28](#acn350909-bib-0028){ref-type="ref"} and Christopoulos et al[29](#acn350909-bib-0029){ref-type="ref"} described treatment‐related neurologic complications among other adverse effects of different conditioning regimens for allo‐HCT; whereas DeFilipp[30](#acn350909-bib-0030){ref-type="ref"} and Kroger[31](#acn350909-bib-0031){ref-type="ref"} reported complications of PNS as well as a patient presented with PRES associated with brentuximab vedotin and lenalidomide used as graft‐versus‐host disease (GVHD) treatment and maintenance, respectively. Van der Wagen et al reported two cases (one viral encephalitis and one Guillain--Barre syndrome) related to the use of rituximab followed by nilotinib as treatment strategy for sclerotic GVHD.[32](#acn350909-bib-0032){ref-type="ref"} Regarding the rest ten prospective studies, immune‐mediated and PNS complications as neuromuscular manifestations of GVHD were examined by Koeppen et al.[33](#acn350909-bib-0033){ref-type="ref"} Beglinger[34](#acn350909-bib-0034){ref-type="ref"} and Scherwath[35](#acn350909-bib-0035){ref-type="ref"} investigated a different type of neurotoxicity of allo‐HCT, that is, cognitive impairment and higher cortical functions. Sostak et al[36](#acn350909-bib-0036){ref-type="ref"} prospectively evaluated a variety of neurologic complications (infectious, cerebrovascular, metabolic, and PNS) after allo‐HCT. Goto et al[37](#acn350909-bib-0037){ref-type="ref"} conducted a prospective observational study on patients treated with peripheral blood stem cell transplantation from unrelated donors and reported a patient's death due to central nervous system disorder. Five additional studies investigated neurologic involvement in infectious diseases caused by protozoa, bacteria, or virus. Finally, in seven of 17 prospective cohorts, neurologic symptoms have been considered to occur early posttransplant. However, this may not be a safe conclusion since not only the follow‐up period is limited in these studies, but also six of them do not report the time that neurologic event occurred. The median follow‐up period of prospective cohort studies was 6 months as estimated by available data from 16 studies.

We classified retrospective cohort studies, respectively, according to the type of neurologic complications. Interestingly, 23 of 86 retrospective studies described more than one type of complication or an encephalopathy of unknown origin making the classification more complex. We found 23 studies exclusively referring to infections and in particular, 13 viral, three fungal, four protozoan, one bacterial and two were about various infections. Sixteen records revealed drug‐related neurologic symptoms. Relapse in CNS was studied in nine records. In addition, only five studies were interested in immune‐mediated and cerebrovascular complications, respectively. TA‐TMA was presented separately only in three studies; whereas PTLD and peripheral complications only in one each. It should be noted that most retrospective cohort studies represent the experience of a center in the adverse effects of allo‐HCT and sometimes specifically neurologic events. Only 38 of 86 studies reported follow‐up period of their cohort and therefore no safe time associated conclusion can be reached. Nevertheless, authors of 47 studies reported that neurologic complications occurred early versus 24 studies that presented late posttransplant events.

Moving on to case series, as described in methods, we extracted data only for those patients eligible for our systematic review. We tracked down 21 studies that fulfilled the previously described criteria. The majority of them, eight studies, traced infectious neurologic manifestations, six immune‐mediated, four drug‐related, two PTLDs, and one metabolic complication. The causative factor was viral in six of eight infectious studies and either bacterial or fungal in each of the ones remaining. Five of six immune‐mediated studies attributed CNS or PNS signs to GVHD. In the sixth one, Stefanou et al[38](#acn350909-bib-0038){ref-type="ref"} studied 61 adult patients who underwent allo‐HCT and had inflammatory polyneuropathy or CNS disease. Finally, drugs specifically responsible for neurologic complications according to authors were cyclosporine, tacrolimus, neralabine and liposomal cytarabine, in three different studies (one in each). In 11 of 21 reports neurologic complications were late events; two did not report that information.

Case reports descriptive characteristics {#acn350909-sec-0015}
----------------------------------------

Taking into consideration the possible publication bias and the vast number of case reports in our systematic review, it would be of value to only describe the variety of the complications presented. As a result, we retrieved 425 case reports: 176 concerned infectious neurologic complications, 109 immune‐mediated, 67 drug‐related mostly related to cyclosporine A or tacrolimus neurotoxicity, 22 relapses of previous hematologic disease, 15 PTLDs, 14 other type, 8 metabolic, 6 TA‐TMA, 4 cerebrovascular neurologic disorders, and 1 disturbance of higher cortical functions. Three references reported infections and one more category (PTLD, TA‐TMA, immune‐mediated) as the cause of the neurologic complication. Overall, 488 patients (≥15 years old) with a neurologic manifestation after allo‐HCT were described. Early posttransplant complications concerned 195 of patients (40%), late 266 (54.5%) of them and in 27 (5.5%) that information was not available. The most common type of neurologic complications was infections in 205 patients (41.9%). The pathogenic cause of infections was viral in 123 (25.2% of total number of patients with neurological manifestations presented as case reports), protozoan in 32 (6.5%), fungal in 34 (6.9%), bacterial in 15 (3.1%) patients and a co‐infection of cerebral toxoplasmosis and HHV‐6 encephalitis in one case (0.2%). The most controversial and recently described[39](#acn350909-bib-0039){ref-type="ref"} entity of neurologic event after allo‐HCT is associated with GVHD and represents 67 of case reports identified in the literature. According to authors, 74 patients had CNS or PNS diseases attributed to acute but mainly chronic GVHD. Immune‐mediated GVHD‐related neurologic diseases included a variety of phenotypes such as myasthenia gravis, polymyositis, Guillain--Barré, encephalitis, vasculitis, and demyelinating complications.

Risk of bias within studies {#acn350909-sec-0016}
---------------------------

The quality of included studies diverged from low to fair. The score of each study is shown in Tables [S4](#acn350909-sup-0001){ref-type="supplementary-material"}, [S5](#acn350909-sup-0001){ref-type="supplementary-material"} and [S6](#acn350909-sup-0001){ref-type="supplementary-material"} (online only). The RCT ranked as high risk applying the Cochrane risk of bias tool.[14](#acn350909-bib-0014){ref-type="ref"}

The maximum NOS score for cohort and case--controls studies was nine stars (four for selection, two for comparability and three for outcome).[13](#acn350909-bib-0013){ref-type="ref"} Six prospective cohort studies were characterized as fair risk and 11 as high risk of bias. Taking into consideration that the majority of prospective cohorts were designed as prospective follow‐up studies and the comparison was made between patients with or without neurologic complications after allo‐HCT, only one scored two stars in comparability part. The only study that matched age and gender of the cohorts from the onset was Beglinger et al[34](#acn350909-bib-0034){ref-type="ref"} that, however, recruited healthy not transplanted controls. Therefore, no prospective cohort study was of low risk of bias. Τhe parts that decisively affected the quality of a study, compared with the others included, were the adequacy of the follow‐up of cohorts and the demonstration that no neurologic manifestation was present before transplantation. The application of NOS on retrospective cohort studies revealed limitations on the selection of nonexposed cohort, adequacy of follow‐up, and presence of outcome of interest before allo‐HCT, deeming most of the studies high or fair risk of bias.

From the two case control studies retrieved, one was of fair risk according to NOS and one of low risk of bias. Conrad et al[24](#acn350909-bib-0024){ref-type="ref"} scored eight of nine stars (low risk) by matching for two factors each case to two controls.

For case series, after the scale proposed by Murad et al[12](#acn350909-bib-0012){ref-type="ref"} was applied, most were deemed as low risk of bias, whereas only six were of fair risk.

Incidence of neurologic events {#acn350909-sec-0017}
------------------------------

In meta‐analysis of proportions performed, we included only cohort studies, retrospective or prospective, with homogenous population to estimate a proportion. We excluded 25 cohort studies with a total population of unclear age. The number of other studies categories (two case--controls and one RCT) and our definition of case series did not allow their usage in the primary outcome of neurologic complication incidence.

Neurologic clinical signs or symptoms were detected in 1415 of 37450 \[6.2% (95% CI 4.8--7.7), *Ι* ^2^ = 96.1% (*P* \< 0.001)\] patients described in 78 included cohort studies (Figure [S1](#acn350909-sup-0001){ref-type="supplementary-material"}‐online only). In our attempt to draw a secure conclusion and because of high heterogeneity, we present the incidence of subtypes of neurologic diseases after allo‐HCT, whenever that was possible, in retrospective and in prospective cohort studies separately. Heterogeneity of results remained high, even after sensitivity analysis excluding studies of high risk of bias (not shown).

Neurologic complications that were most frequently reported were central nervous system infection and drug‐related events.

As presented in the forest plots of Figures [2](#acn350909-fig-0002){ref-type="fig"} and [3](#acn350909-fig-0003){ref-type="fig"}, infectious involvement of nervous system after allo‐HCT was present in 2.7% (95% CI 1.9--3.6), *Ι* ^2^ = 86.5% (*P* \< 0.001) and in 3.3% (95% CI 0.8--7.1), *Ι* ^2^ = 90.0% (*P* \< 0.001) of patients, in retrospective and prospective cohort studies, respectively.

![Forest plot of retrospective cohort studies reporting infectious neurological complications.](ACN3-6-2037-g002){#acn350909-fig-0002}

![Forest plot of prospective cohort studies reporting infectious neurological complications.](ACN3-6-2037-g003){#acn350909-fig-0003}

Then, we examined the incidence of the second most frequently reported neurologic type of complication, drug‐related events. Overall, in retrospective studies 3.4% (95% CI 2.1--4.9), *Ι* ^2^ = 76.4% (*P* \< 0.001) of the population suffered from neurologic symptoms associated with drugs used during allo‐HCT (Fig. [4](#acn350909-fig-0004){ref-type="fig"}). However, in prospective cohorts the equivalent incidence was higher representing 13% (95% CI 4.2--24.8), *Ι* ^2^ = 86.6% (*P* \< 0.001) of the total population (Fig. [5](#acn350909-fig-0005){ref-type="fig"}).

![Forest plot of retrospective cohort studies reporting drug‐related neurological complications.](ACN3-6-2037-g004){#acn350909-fig-0004}

![Forest plot of prospective cohort studies reporting infectious neurological complications.](ACN3-6-2037-g005){#acn350909-fig-0005}

The pooled rates of cerebrovascular events, TA‐TMA, immune‐mediated, relapse in CNS, and metabolic neurologic events originated from retrospective cohorts of fair risk of bias as shown in Figures [S2](#acn350909-sup-0001){ref-type="supplementary-material"} to S6 (online only). Immune‐mediated diseases remain a challenging diagnosis after allo‐HCT. We observed a relatively low incidence of 0.6% (95%CI 0.3‐0.9), supported by low heterogeneity *Ι* ^2^ = 36.2% (*P* \< 0.001). We observed an incidence of 2.2% (95% CI 1.2--3.5), *Ι* ^2^ = 86.6% (*P* \< 0.001) for cerebrovascular diseases. Many studies did not include CNS relapse of the original disease as a neurologic event after allo‐HCT. In retrospective cohorts that presented CNS relapse after allo‐HCT the resulting incidence was 2.3 % (95% CI 0.9--4.3), *Ι* ^2^ = 93.7% (*P* \< 0.001). The definition of metabolic encephalopathy or complication was hardly predetermined in studies. The incidence of neurologic complications attributed to metabolic type was 2.4% (95% CI 1.1--4.1), *Ι* ^2^ = 82.5% (*P* \< 0.001). Interestingly, ΤΑ‐ΤΜΑ incidence (with neurologic manifestation at diagnosis) was 3.4% (95% CI 1.7--5.6) *Ι* ^2^ = 84.9% (*P* \< 0.001) suggesting that is not a rare neurologic event after allo‐HCT.

Higher cortical functions, peripheral not otherwise specified, PTLD, and other types of neurologic complications did not provide sufficient data to be part of the analysis.

Case fatality rate {#acn350909-sec-0018}
------------------

The secondary endpoint of our study was the interpretation of the impact of neurologic events in the survival of patients after allo‐HCT. We decided not to calculate any death rate as summary measure, due to high heterogeneity between studies, types of complications, and study populations. Therefore, we describe fatal events for each study type separately.

In case reports, fatal outcome was related to neurologic complications in 124 of 489 (25.4%) cases. Eight case reports did not address the outcome of the case. In 21 case series, the number of deaths attributed to neurologic complications ranged from 0 to 100% with a median of 29%. This information was not available in six studies. Regarding case--controls studies, only Conrad et al[24](#acn350909-bib-0024){ref-type="ref"} provided the number of fatal neurologic cases leading to a 60% rate (6/10) of patients with neurologic events. The majority of prospective cohorts, 11/17 studies, did not examine the outcome of patients with neurologic complications. Therefore, in the six studies with available information death due to neurologic complications ranged from 0 to 100% with a median of 25%. Finally, we could not extract the outcome of neurologic events for 804/1700 patients with neurologic symptoms in 34 retrospective cohort studies. Mortality of patients with neurologic complication in the remaining retrospective cohorts ranged from 0 to 100% with a median of 25.5%. In the one RCT included in the systematic review, one patient of the methotrexate and one of the cyclosporine group died of cerebral hemorrhage and encephalopathy, respectively, resulting in a case fatality rate of 12.5% among patients with neurologic symptoms.

Risk of bias across studies and publication bias {#acn350909-sec-0019}
------------------------------------------------

Based on study type, high risk of bias in most of the included studies, as well as significant heterogeneity in results that come from observational data, high imprecision, and suspected publication bias (Egger's test and funnel plot not shown), quality of evidence was very low applying the GRADE tool (Table [S7](#acn350909-sup-0001){ref-type="supplementary-material"}‐online only)[15](#acn350909-bib-0015){ref-type="ref"}.

Discussion {#acn350909-sec-0020}
==========

Summary of evidence {#acn350909-sec-0021}
-------------------

Our systematic review and meta‐analysis highlights and classifies the wide spectrum of neurologic complications in patients post allo‐HCT for hematologic diseases. Incidence rates varied, according to type of complications and studies, from 0.6% for immune‐mediated disorders in retrospective cohorts to 13% for drug‐related events in prospective cohorts. This can be attributed to the fact that most studies examined a selected population that received a certain treatment in a limited time period. Interestingly, the majority of these complications occurred early as well as late posttransplant rendering long‐term increased awareness of treating physicians of utmost importance. Nevertheless, no valid conclusions can be drawn taking into consideration the lack of information about the follow‐up period in many studies and the diversity of treatment regimens.

Regarding severity of neurologic complications and death rate in patients with outcome of interest, data were too diverse to provide any safe conclusion. This was mainly explained by different neurologic events (e.g., intracranial hemorrhage could not be compared with cognitive impairment in terms of mortality) as well as the different treatment regimens and study designs. Furthermore, considering the multimorbidity of allo‐HCT recipients, including multiple organ failure and disease relapse, death could rarely be attributed to neurologic events alone. Therefore, mortality rates due to neurologic complications might have been underestimated in many studies.

Results in context of existing evidence {#acn350909-sec-0022}
---------------------------------------

To our knowledge, this is, the first systematic review that addresses the chaotic subject of neurologic complications after allo‐HCT and its impact on survival. Scheurer et al[40](#acn350909-bib-0040){ref-type="ref"} carried out a systematic review investigating a subtype of neurologic episodes, HHV‐6 encephalitis in umbilical cord blood transplantation (CBT). This study included both pediatric and adult population and selected a specific type of allo‐HCT. The pooled prevalence of HHV‐6 encephalitis among patients who underwent CBT was 8.3% and 0.5% for stem cell source other than cord blood. Due to nonequivalent patient population, no comparison can be made with the incidence for infectious neurologic events.[36](#acn350909-bib-0036){ref-type="ref"}

The involvement of CNS or PNS in GVHD was not proven until recently and still remains a challenging diagnosis.[41](#acn350909-bib-0041){ref-type="ref"} We present that an important number of studies addressing this issue, mostly case reports, were published during the last decade.[42](#acn350909-bib-0042){ref-type="ref"} Interestingly, in our meta‐analysis the pooled incidence of immune‐mediated disorders including GVHD was 0.6% (95% CI 0.3--0.9) with low heterogeneity *Ι* ^2^ = 36.2% (*P* \< 0.001). On the contrary, TA‐TMA with neurologic dysfunction incidence was found to be high compared to other types \[3.4% (95% CI 1.7--5.6) *Ι* ^2^ = 84.9% (*P* \< 0.001)\] in accordance with previous studies.[43](#acn350909-bib-0043){ref-type="ref"}

Regarding the secondary outcome, neurologic complications are considered to be devastating events after allo‐HCT according to observational data and single‐center experiences. No systematic review has ever been conducted to support that theory. Scarce data can be found in Lin et al[44](#acn350909-bib-0044){ref-type="ref"} who studied aspergillosis (not only in CNS) and reported a case fatality rate of 86.7% in transplanted patient. Moreover, in the meta‐analysis of van de Peppel[45](#acn350909-bib-0045){ref-type="ref"} the case fatality rate for patients (who not necessarily underwent allo‐HCT) with proven invasive aspergillosis in CNS was 72%. We report a wide variety of burden of neurologic complications after allo‐HCT according to study type ranging from minor 12.5% as reported in the RCT to devastating 60% of case--control studies. However, in retrospective cohorts the outcome of 896 patients was reported and case fatality rate ranged from 0 to 100% with median 25.5%. This variability should be explained with caution due to the described heterogeneity of neurologic signs and symptoms, definition of those events and diagnostic strategy of each center, the variety of hematologic transplant procedures, study designs and the indefinable follow‐up period. It should be noted that most data in this review emerge from real‐world retrospective studies that lack appropriate methodology to reach safe conclusions. This fact not only reflects the complexity of the field but also the need for a systematic approach in future studies.

Strengths and limitations of study {#acn350909-sec-0023}
----------------------------------

Our study incorporated a large amount of information about different types of neurologic complications in allo‐HCT recipients coming from studies of inferior quality. This can be considered strength of the present systematic review as we tried to be as inclusive as possible, following a comprehensive search strategy and accepting all study types despite the limitation of increased heterogeneity. We provided therefore a systematic review of all available information on the subject.

However, our study has several limitations translated into different sources of bias. First, our systematic review incorporated studies that included patients with disease relapse posttransplant in an effort to describe the broad spectrum of neurologic adverse events, in spite of the presence of CNS disease pre and posttransplant. Second, we studied only papers in English introducing possible selection bias. Moreover, our meta‐analysis resulted in noticeable heterogeneity even after subgroup and sensitivity analysis. However, this was expected taking into consideration the lack of specific guidelines for the definition of neurologic complications after HCT and the variability of transplantation procedures. Finally, in our review we decided to assess publication bias with usual methods, acknowledging, however, their limitations in this particular occasion of one arm studies.[21](#acn350909-bib-0021){ref-type="ref"} This resulted in detection of probable publication bias which may be overestimated in our study.

Implications {#acn350909-sec-0024}
------------

The aim of this systematic review was to provide all existing evidence in the literature in the form of the highest level of the pyramid of evidence‐based medicine, to clinical physicians. For the consultant neurologist with a specific interest in this field, it is important to maintain a high index of suspicion in certain subgroups of patients. Thus, long‐term increased awareness even during the late posttransplant period and collaboration between expert physicians is necessary to improve patient outcomes.

Further research with methodologically well‐organized studies is likely to establish solid recommendations about the incidence, type, and treatment of neurologic complications after HCT.

Conclusions {#acn350909-sec-0025}
-----------

In conclusion, various types of neurologic complications can be confronted in adult patients after allo‐HCT even as late events. This systematic review summarizes existing data and provides the necessary background information for every physician involved in the management of these patients. The neurologic incidence varies a lot between treatment regimens and types of neurologic complications and treating hematologists should bear in mind the broadness of the subject for best interest of this special group of patients.
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